RMD ResMed
Sleep apnea duopoly leader with recurring mask revenue; fairly priced unless GLP-1 fears come true.
The story
ResMed is the global leader in CPAP devices and masks for sleep apnea. Its moat comes from a large installed base, recurring mask and accessory resupply revenue, and a connected-device and software ecosystem (AirView, myAir, Brightree/MatrixCare) that ties it into payer and DME workflows. Philips' recall handed ResMed share and pricing power, and fears that GLP-1 drugs would shrink demand have so far not shown up in patient flow. The company is a maturing, highly profitable franchise with a long runway, because sleep apnea remains heavily underdiagnosed worldwide.
I set growth at 8%, a bit below the roughly 10% five-year CAGR, to reflect GLP-1 drag and Philips' gradual return to the US market. I put the margin at 33%, just under the current 34.7% peak, because competition will likely erode some of the post-recall pricing. The reported sales-to-capital of 0.79 is held down by acquisition goodwill, while incremental capital needs are light (capex is about 3% of sales), so I use 1.6. A 10-year horizon fits a durable duopoly with an underpenetrated market, and these drivers come out close to the current market price instead of the baseline's 140.
Value drivers
| Revenue growth (Y1) | 8.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 33.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.60 |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 11.81B |
| PV of terminal value | 15.85B |
| Equity value | 28.18B |
| ÷ shares → per share | $200.36 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.19B | 8.0% | 34.1% | 1.68B | 286.63M | 1.39B | 1.28B |
| 2 | 6.66B | 7.5% | 33.6% | 1.77B | 290.22M | 1.48B | 1.26B |
| 3 | 7.12B | 7.0% | 33.0% | 1.87B | 291.18M | 1.57B | 1.23B |
| 4 | 7.58B | 6.5% | 33.0% | 1.99B | 289.31M | 1.70B | 1.22B |
| 5 | 8.04B | 6.0% | 33.0% | 2.11B | 284.42M | 1.82B | 1.20B |
| 6 | 8.48B | 5.5% | 33.0% | 2.22B | 276.36M | 1.94B | 1.18B |
| 7 | 8.91B | 5.0% | 33.0% | 2.33B | 265.05M | 2.07B | 1.16B |
| 8 | 9.31B | 4.5% | 33.0% | 2.44B | 250.47M | 2.19B | 1.13B |
| 9 | 9.68B | 4.0% | 33.0% | 2.53B | 232.66M | 2.30B | 1.09B |
| 10 | 10.02B | 3.5% | 33.0% | 2.62B | 211.72M | 2.41B | 1.06B |
Key risks
- GLP-1 drugs reduce how many patients get diagnosed and treated, or how long they stay on therapy
- Philips' full return to the US market pressures device pricing and share
- Reimbursement cuts or competitive bidding at CMS and international payers
Catalysts
- Real-world data showing GLP-1 users start and stay on PAP therapy at higher rates
- Gross margin gains from manufacturing efficiencies and mask mix, plus growth in the SaaS segment